Pharmaceutical care of anti-infective treatment for a case of pulmonary infection due to Alternaria alternata after renal transplantation
- VernacularTitle:1例肾移植术后互隔链格孢菌致肺部感染患者抗感染治疗的药学监护
- Author:
Ruixia ZHANG
1
;
Yanping WANG
2
;
Shan GAO
3
Author Information
1. Dept. of Pharmacy，Tianjin First Central Hospital，Tianjin 300192，China
2. Dept. of Pharmacy，Tianjin Anding Hospital，Tianjin 300222，China
3. Dept. of Pharmacy，Tangshan Maternal and Child Health Hospital，Hebei Tangshan 063000，China
- Publication Type:Journal Article
- Keywords:
Alternaria alternate;
fungal infection;
kidney transplantation;
pharmaceutical monitoring
- From:
China Pharmacy
2025;36(4):491-495
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To provide a reference for the selection of anti-infection schemes and pharmaceutical monitoring of pulmonary infection due to Alternaria alternata after renal transplantation. METHODS The clinical pharmacist was involved in the anti-infective treatment of a patient with pulmonary infection caused by A. alternata after renal transplantation. After considering the patient’s clinical symptoms， laboratory test results， and pertinent literature， clinical pharmacists determined that the patient may have developed pulmonary infection as a result of respiratory allergy due to A. alternata. The potential for infections from both Legionella and adenovirus remained a possibility. Oral administration of Voriconazole tablets was recommended for fungal therapy， while Moxifloxacin tablets were suggested for treating Legionella. Additionally， it was advised to lower the dosage of tacrolimus and stop using ganciclovir. The pharmacists meticulously tracked the patient’s voriconazole trough levels and any adverse effects that might arise during the therapy. RESULTS The physician endorsed the clinical pharmacist’s recommendations， and the patient’s status was steady， permitting discharge. CONCLUSIONS A. alternata is a potential pathogen for immunosuppressed patients， particularly when they also experience respiratory allergic reactions. Voriconazole can serve as the first-line treatment for anti-infection therapy. Clinical pharmacists ensure the patient medication safety by adjusting the dosage of voriconazole， extending the treatment course， monitoring liver and visual functions， and being vigilant about the interaction between voriconazole and immunosuppressants.
